| Trial ID: | L0632 |
| Source ID: | NCT02077374
|
| Associated Drug: |
IDN-6556
|
| Title: |
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases
|
| Acronym: |
NAFLD
|
| Status: |
Not recruiting
|
| Study Results: |
Has Results
|
| Results: |
https://clinicaltrials.gov/ct2/show/results/NCT02077374
|
| Conditions: |
Nonalcoholic Steatohepatitis;Non-alcoholic Fatty Liver Disease;Nonalcoholic Steatohepatitis;Non-alcoholic Fatty Liver Disease;Nonalcoholic Steatohepatitis;Non-alcoholic Fatty Liver Disease;Nonalcoholic Steatohepatitis;Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: IDN-6556;Other: Placebo;Drug: IDN-6556;Other: Placebo;Drug: IDN-6556;Other: Placebo;Drug: IDN-6556;Other: Placebo
|
| Outcome Measures: |
Change in Alanine Aminotransferase (ALT);Relative Percent Change in Alanine Aminotransferase (ALT);Change in Alanine Aminotransferase (ALT);Relative Percent Change in Alanine Aminotransferase (ALT)Change in Aspartate Aminotransferase (AST);Levels of cCK18/M30;Levels of Caspase 3/7 RLU;Levels of flCK18/M65
|
| Sponsor/Collaborators: |
Conatus Pharmaceuticals Inc.
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Phase 2
|
| Enrollment: |
38
|
| Study Type: |
Interventional
|
| Study Designs: |
--
|
| Start Date: |
28/02/2014
|
| Completion Date: |
--
|
| Results First Posted: |
21/07/2016
|
| Last Update Posted: |
19 October 2017
|
| Locations: |
United States;United States;United States;United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02077374
|
